A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

NCT07083388 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg
DRUG: Dapagliflozin 10 mg
DRUG: Pioglitazone 30 mg
DRUG: Metformin HCl 1000 mg

Sponsor

Boryung Pharmaceutical Co., Ltd